Literature DB >> 7786567

Measuring health status with the SF-36: the need for regional norms.

R A Lyons1, H Fielder, B N Littlepage.   

Abstract

BACKGROUND: Normative data on SF-36 scores in populations from Oxford and Aberdeen have recently been published. It has been suggested that such data provide suitable normative values for the UK population. However, other indices of health vary considerably across regions, and tend to be worse in areas such as South Wales. The objective of this study was to determine whether population SF-36 scores in West Glamorgan differ from scores from other parts of the United Kingdom.
METHOD: The SF-36 health status questionnaire was administered to two random samples of adults aged 20-89 years, drawn from the West Glamorgan Family Health Services Authority register. One sample (n = 919) received postal questionnaires and those in the other sample (n = 1201) were interviewed in their own homes. Normative data from this study were compared with published data from other areas of the United Kingdom.
RESULTS: SF-36 population scores were significantly lower in the two West Glamorgan samples; this was not due to differences in age, sex, social class, or response rates.
CONCLUSION: Health status in West Glamorgan, as measured by the SF-36, is lower than in Oxford or Aberdeen. A national study would be required to provide appropriate normative data for the UK population.

Mesh:

Year:  1995        PMID: 7786567

Source DB:  PubMed          Journal:  J Public Health Med        ISSN: 0957-4832


  12 in total

1.  How much does self-reported health status, measured by the SF-36, vary between electoral wards with different Jarman and Townsend scores?

Authors:  P Marsh; R Carlisle; A J Avery
Journal:  Br J Gen Pract       Date:  2000-08       Impact factor: 5.386

2.  Evidence for the sensitivity of the SF-36 health status measure to inequalities in health: results from the Oxford healthy lifestyles survey.

Authors:  C Jenkinson; R Layte; A Coulter; L Wright
Journal:  J Epidemiol Community Health       Date:  1996-06       Impact factor: 3.710

3.  Postal questionnaire study of disability in the community associated with psoriasis.

Authors:  P O'Neill; P Kelly
Journal:  BMJ       Date:  1996-10-12

4.  Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group.

Authors:  W M Hopman; T Towheed; T Anastassiades; A Tenenhouse; S Poliquin; C Berger; L Joseph; J P Brown; T M Murray; J D Adachi; D A Hanley; E Papadimitropoulos
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

5.  Psychosocial aetiology of chronic disease: a pragmatic approach to the assessment of lifetime affective morbidity in an EPIC component study.

Authors:  P G Surtees; N W Wainwright; C Brayne
Journal:  J Epidemiol Community Health       Date:  2000-02       Impact factor: 3.710

6.  Longer term quality of life and outcome in stroke patients: is the Barthel index alone an adequate measure of outcome?

Authors:  P R Wilkinson; C D Wolfe; F G Warburton; A G Rudd; R S Howard; R W Ross-Russell; R Beech
Journal:  Qual Health Care       Date:  1997-09

7.  Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial.

Authors:  P Murchie; M C Nicolson; P C Hannaford; E A Raja; A J Lee; N C Campbell
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

8.  Self-perceived health status of Irish breast cancer survivors.

Authors:  M B O'Sullivan
Journal:  Ir J Med Sci       Date:  2001 Jan-Mar       Impact factor: 2.089

9.  The impact of socioeconomic status on health functioning as assessed by the SF-36 questionnaire: the Whitehall II Study.

Authors:  H Hemingway; A Nicholson; M Stafford; R Roberts; M Marmot
Journal:  Am J Public Health       Date:  1997-09       Impact factor: 9.308

10.  Genetic nurse counsellors can be an acceptable and cost-effective alternative to clinical geneticists for breast cancer risk genetic counselling. Evidence from two parallel randomised controlled equivalence trials.

Authors:  N Torrance; J Mollison; S Wordsworth; J Gray; Z Miedzybrodzka; N Haites; A Grant; M Campbell; M S Watson; A Clarke; B Wilson
Journal:  Br J Cancer       Date:  2006-07-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.